{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:29:42Z","timestamp":1773278982673,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,7,14]],"date-time":"2009-07-14T00:00:00Z","timestamp":1247529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s11904-009-0017-9","type":"journal-article","created":{"date-parts":[[2009,7,13]],"date-time":"2009-07-13T05:55:02Z","timestamp":1247464502000},"page":"121-129","source":"Crossref","is-referenced-by-count":24,"title":["Impact of metabolic complications on antiretroviral treatment adherence: Clinical and public health implications"],"prefix":"10.1007","volume":"6","author":[{"given":"Jean B.","family":"Nachega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paola","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Ammassari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,14]]},"reference":[{"key":"17_CR1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00126334-200312010-00008","volume":"34","author":"M.E. O\u2019Brien","year":"2003","unstructured":"O\u2019Brien ME, Clark RA, Besch CL, et al.: Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003, 34:407\u2013414.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"17_CR2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1086\/507333","volume":"43","author":"D.A. Wohl","year":"2006","unstructured":"Wohl DA, McComsey G, Tebas P, et al.: Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006, 43:645\u2013653.","journal-title":"Clin Infect Dis"},{"key":"17_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-9343(02)01156-7","volume":"113","author":"L.A. Lenert","year":"2002","unstructured":"Lenert LA, Feddersen M, Sturley A, Lee D: Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med 2002, 113:229\u2013232.","journal-title":"Am J Med"},{"key":"17_CR4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/apc.2007.0069","volume":"22","author":"A.M. Vranceanu","year":"2008","unstructured":"Vranceanu AM, Safren SA, Lu M, et al.: The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDS 2008, 22:313\u2013321.","journal-title":"AIDS Patient Care STDS"},{"key":"17_CR5","unstructured":"Ammassari A, Cozzi-Lepri A, Trotta MP, et al.: ICoNA Cohort: Treatment complexity and risk of virological rebound in persons receiving cART [abstract 522]. Programs and Abstracts for the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25\u201328, 2007."},{"key":"17_CR6","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/QAD.0b013e32830efd79","volume":"22","author":"J.H. Willig","year":"2008","unstructured":"Willig JH, Abroms S, Westfall AO, et al.: Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008, 22:1951\u20131960.","journal-title":"AIDS"},{"key":"17_CR7","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1371\/journal.pmed.0030438","volume":"3","author":"E.J. Mills","year":"2006","unstructured":"Mills EJ, Nachega JB, Bangsberg DR, et al.: Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006, 3:e438.","journal-title":"PLoS Med"},{"key":"17_CR8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00002030-200003310-00005","volume":"14","author":"A. d\u2019Arminio Monforte","year":"2000","unstructured":"d\u2019Arminio Monforte A, Lepri AC, Rezza G, et al.: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral na\u00efve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Na\u00efve Patients. AIDS 2000, 14:499\u2013507.","journal-title":"AIDS"},{"key":"17_CR9","unstructured":"Amoroso A, Sheneberger R, Edozien A, et al.: Antiretroviral-associated drug toxicities leading to a switch in medication: experience in Uganda, Kenya, and Zambia [poster 587]. In Programs and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25\u201328, 2007. Available at http:\/\/www.retroconference.org\/2007\/PDFs\/789.pdf . Accessed April 10, 2009."},{"key":"17_CR10","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(07)61790-5","volume":"370","author":"E.J. Mills","year":"2007","unstructured":"Mills EJ, Nachega JB: A wake up call for global access to salvage HIV regimens. Lancet 2007, 370:1885\u20131887.","journal-title":"Lancet"},{"key":"17_CR11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389450033347109","volume":"4","author":"K.V. Heath","year":"2003","unstructured":"Heath KV, Montaner JS, Bondy G, et al.: Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Curr Drug Targets 2003, 4:13\u201322.","journal-title":"Curr Drug Targets"},{"key":"17_CR12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00042560-200112150-00006","volume":"28","author":"A. Ammassari","year":"2001","unstructured":"Ammassari A, Murri R, Pezzotti P, et al.; AdICONA Study Group: Self-reported symptoms and medications side effects influence adherence to HAART in persons with HIV infection. J Acquir Immune Defic Syndr 2001, 28:445\u2013449.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"17_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1310\/R8M7-EQ0M-CNPW-39FC","volume":"2","author":"S. Duran","year":"2001","unstructured":"Duran S, Spire B, Raffi F, et al.: Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001, 2:38\u201345.","journal-title":"HIV Clin Trials"},{"key":"17_CR14","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","volume":"19","author":"M.P. Dube","year":"2005","unstructured":"Dube MP, Parker RA, Tebas P, et al.: Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005, 19:1807\u20131818.","journal-title":"AIDS"},{"key":"17_CR15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/09540120701294245","volume":"19","author":"T.W. Kim","year":"2007","unstructured":"Kim TW, Palepu A, Cheng DM, et al.: Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems. AIDS Care 2007, 19:1039\u20131047.","journal-title":"AIDS Care"},{"key":"17_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1310\/W1QF-C9X9-9PFT-88JK","volume":"4","author":"G. Guaraldi","year":"2003","unstructured":"Guaraldi G, Murri R, Orlando G, et al.: Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials 2003, 4:99\u2013106.","journal-title":"HIV Clin Trials"},{"key":"17_CR17","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/383573","volume":"38","author":"J. Blanch","year":"2004","unstructured":"Blanch J, Rousaud A, Mart\u00ednez E, et al.: Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004, 38:1464\u20131470.","journal-title":"Clin Infect Dis"},{"key":"17_CR18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/sti.79.2.137","volume":"79","author":"R. Power","year":"2003","unstructured":"Power R, Tate HL, McGill SM, Taylor C: A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003, 79:137\u2013141.","journal-title":"Sex Transm Infect"},{"key":"17_CR19","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","volume":"15","author":"K.A. Lichtenstein","year":"2001","unstructured":"Lichtenstein KA, Ward DJ, Morman AC, et al.: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389\u20131398.","journal-title":"AIDS"},{"issue":"Supp3","key":"17_CR20","first-page":"15","volume":"10","author":"R.A. Parker","year":"2005","unstructured":"Parker RA, Komarow L, Grinspoon KK, et al.: Baseline and early on-treatment predictors of lipoatrophy at week 64 in a randomized trial of initial antiretroviral therapy: a secondary analysis of A5005s, a substudy of ACTG 384. Seventh International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, in Dublin, Ireland. Antivir Ther 2005, 10(Supp 3):15\u201316.","journal-title":"Antivir Ther"},{"key":"17_CR21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","volume":"14","author":"S.A. Mallal","year":"2000","unstructured":"Mallal SA, John M, Moore CB, et al.: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309\u20131316.","journal-title":"AIDS"},{"key":"17_CR22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"J.E. Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191\u2013201.","journal-title":"JAMA"},{"key":"17_CR23","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","volume":"354","author":"K. Brinkman","year":"1999","unstructured":"Brinkman K, Smeitink JA, Romijn JA, et al.: Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy lipodystrophy. Lancet 1999, 354:1112\u20131115.","journal-title":"Lancet"},{"key":"17_CR24","doi-asserted-by":"crossref","first-page":"14711","DOI":"10.1021\/bi035596s","volume":"42","author":"H. Lee","year":"2003","unstructured":"Lee H, Hanes J, Johnson KA: Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003, 42:14711\u201314719.","journal-title":"Biochemistry"},{"key":"17_CR25","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/01.qai.0000138420.38995.86","volume":"37","author":"P.E. Sax","year":"2004","unstructured":"Sax PE, Kumar P: Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004, 37:1111\u20131124.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"17_CR26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","volume":"12","author":"A. Milinkovic","year":"2007","unstructured":"Milinkovic A, Martinez E, L\u00f3pez S, et al.: The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007, 12:407\u2013415.","journal-title":"Antivir Ther"},{"key":"17_CR27","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","volume":"20","author":"G.J. Moyle","year":"2006","unstructured":"Moyle GJ, Sabin CA, Cartledge J, et al.: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006, 20:2043\u20132050.","journal-title":"AIDS"},{"key":"17_CR28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","volume":"44","author":"D. Podzamczer","year":"2007","unstructured":"Podzamczer D, Ferrer E, Sanchez P, et al.; ABCDE (Abacavir vs. d4T [Stavudine] Plus Efavirenz) Study Team: Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007, 44:139\u2013147.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"17_CR29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","volume":"354","author":"J.E. Gallant","year":"2006","unstructured":"Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251\u2013260.","journal-title":"N Engl J Med"},{"key":"17_CR30","unstructured":"Moyle G, Fisher M; SWEET study group: A randomized comparison of continued zidovudine plus lamivudine BID (AZT\/3TC) vs switching to tenofovir DF plus emtricitabine (FTC\/TDF) each plus efavirenz (EFV) in stable HIV infected persons: 48 week study\u2014results of a planned 24 week analysis [abstract WEPEB028]. In Program and Abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; July 22\u201325, 2007."},{"key":"17_CR31","unstructured":"Cooper V, Horne R, Moyle G, et al.: Simplification with Easier Emtricitabine and Tenofovir (SWEET): results of a 48 week analysis of patients\u2019 perceptions of treatment and adherence [poster TUPE0065]. Programs and Abstracts of the XVII International AIDS Conference. Mexico City, Mexico; August 3\u20138, 2008."},{"key":"17_CR32","unstructured":"Tebas P: Metabolic toxicities and impact on adherence. Second Botswana International HIV\/AIDS Conference. Gaborone, Botswana; September 17\u201320, 2008. Available at http:\/\/www.botshiv.org.bw\/view_details.php?name=SAHIV%20Conference%202008 . Accessed April 11, 2009."},{"key":"17_CR33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","volume":"352","author":"S. Grinspoon","year":"2005","unstructured":"Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48\u201362.","journal-title":"N Engl J Med"},{"key":"17_CR34","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","volume":"1","author":"F. Leth van","year":"2004","unstructured":"van Leth F, Phanuphak P, Stroes E, et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. Plos Med 2004, 1:e19.","journal-title":"Plos Med"},{"key":"17_CR35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1258\/0956462011923507","volume":"12","author":"E.N. Vergis","year":"2001","unstructured":"Vergis EN, Paterson DL, Wagener MM, et al.: Dyslipidaemia in HIV-infected patient: association with adherence to highly active antiretroviral therapy. Int J STD AIDS 2001, 12:463\u2013468.","journal-title":"Int J STD AIDS"},{"key":"17_CR36","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.aids.0000174451.78497.8f","volume":"19","author":"L. Calza","year":"2005","unstructured":"Calza L, Manfredi R, Colangeli V, et al.: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005, 19:1051\u20131058.","journal-title":"AIDS"},{"key":"17_CR37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/08998280.2007.11928265","volume":"20","author":"J.E. Bury","year":"2007","unstructured":"Bury JE, Stroup JS, Stephens JR, Baker DL: Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitus. Proc (Bayl Univ Med Cent) 2007, 20:118\u2013123.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"Suppl","key":"17_CR38","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"E.S. Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, et al.: Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009, 122(Suppl):S3\u2013S13.","journal-title":"Am J Med"},{"key":"17_CR39","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-200003100-00005","volume":"14","author":"P. Tebas","year":"2000","unstructured":"Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63\u2013F67.","journal-title":"AIDS"},{"key":"17_CR40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/498511","volume":"42","author":"V. Amorosa","year":"2006","unstructured":"Amorosa V, Tebas P: Bone disease and HIV infection. Clin Infect Dis 2006, 42:108\u2013114.","journal-title":"Clin Infect Dis"},{"key":"17_CR41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/QAD.0b013e3280148c05","volume":"21","author":"J.H. Arnsten","year":"2007","unstructured":"Arnsten JH, Freeman R, Howard AA, et al.: Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007, 21:617\u2013623.","journal-title":"AIDS"},{"key":"17_CR42","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","volume":"20","author":"T.T. Brown","year":"2006","unstructured":"Brown TT, Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165\u20132174.","journal-title":"AIDS"},{"key":"17_CR43","doi-asserted-by":"crossref","unstructured":"Collin F, Duvan X, Le Moing V, et al.: Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009 Mar 19 (Epub ahead of print).","DOI":"10.1097\/QAD.0b013e3283292195"},{"key":"17_CR44","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1185\/03007990802115796","volume":"24","author":"S. Boonen","year":"2008","unstructured":"Boonen S, Singer AJ: Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture I. Curr Med Res Opin 2008, 24:1781\u20131788.","journal-title":"Curr Med Res Opin"},{"key":"17_CR45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S8756-3282(02)00787-1","volume":"31","author":"A.R. Martin","year":"2002","unstructured":"Martin AR, Sornay-Rendu E, Chandler JM, et al.: The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone 2002, 31:32\u201336.","journal-title":"Bone"},{"key":"17_CR46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.qai.0000145352.04440.1e","volume":"38","author":"K. Mondy","year":"2005","unstructured":"Mondy K, Powderly W, Claxton SA, et al.: Alendronate, vitamin D, and calcium for the treatment of osteopenia\/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005, 38:426\u2013431.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"17_CR47","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1345\/aph.1K465","volume":"42","author":"P.G. Clay","year":"2008","unstructured":"Clay PG, Voss LE, Williams C, Daume EC: Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacother 2008, 42:670\u2013679.","journal-title":"Ann Pharmacother"},{"key":"17_CR48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1212\/01.wnl.0000339042.96109.86","volume":"72","author":"N. Sacktor","year":"2009","unstructured":"Sacktor N, Nakasujja N, Skolasky RL, et al.: Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009, 72:165\u2013170.","journal-title":"Neurology"},{"key":"17_CR49","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0b013e318186eb03","volume":"49","author":"P. Sithinamsuwan","year":"2008","unstructured":"Sithinamsuwan P, Punthanamongkol S, Valcour V, et al.: Frequency and characteristics of HIV-associated sensory neuropathy among HIV patients in Bangkok, Thailand. J Acquir Immune Defic Syndr 2008, 49:456\u2013458.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"17_CR50","first-page":"237","volume":"9","author":"J. Collazos","year":"2007","unstructured":"Collazos J: Sexual dysfunction in the highly active antiretroviral therapy era. AIDS Rev 2007, 9:237\u2013245.","journal-title":"AIDS Rev"},{"key":"17_CR51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10461-006-9197-0","volume":"12","author":"M.J. Miguez-Burbano","year":"2008","unstructured":"Miguez-Burbano MJ, Espinoza L, Lewis JE: HIV treatment adherence and sexual functioning. AIDS Behav 2008, 12:78\u201385.","journal-title":"AIDS Behav"},{"key":"17_CR52","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/apc.2007.0061","volume":"22","author":"M.P. Trotta","year":"2008","unstructured":"Trotta MP, Ammassari A, Murri R, et al.: Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals. AIDS Patient Care STDS 2008, 22:291\u2013299.","journal-title":"AIDS Patient Care STDS"},{"key":"17_CR53","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00042560-200206010-00007","volume":"30","author":"F. Lallemand","year":"2002","unstructured":"Lallemand F, Salhi Y, Linard F, et al.: Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr 2002, 30:187\u2013190.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"17_CR54","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(07)60446-2","volume":"369","author":"M.P. Trotta","year":"2007","unstructured":"Trotta MP, Ammassari A, Murri R, et al.: Sexual dysfunction in HIV infection. Lancet 2007, 369:905\u2013906.","journal-title":"Lancet"},{"key":"17_CR55","first-page":"211","volume":"39","author":"C. Diamond","year":"2005","unstructured":"Diamond C, Richardson JL, Milam J, et al.; California Collaborative Trials Group: Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. J Acquir Immune Defic Syndr 2005, 39:211\u2013218.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"17_CR56","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/521150","volume":"45","author":"R. Subbaraman","year":"2007","unstructured":"Subbaraman R, Chaguturu SK, Mayer KH, et al.: Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007, 45:1093\u20131101.","journal-title":"Clin Infect Dis"},{"key":"17_CR57","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1089\/aid.2008.0083","volume":"24","author":"L.S. Robison","year":"2008","unstructured":"Robison LS, Westfall AO, Mugavero MJ, et al.: Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 2008, 24:1347\u20131355.","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-009-0017-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-009-0017-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-009-0017-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T23:48:43Z","timestamp":1685058523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-009-0017-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,14]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["17"],"URL":"https:\/\/doi.org\/10.1007\/s11904-009-0017-9","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,14]]}}}